Atorlip 10: Effective LDL Cholesterol Management for Cardiovascular Health
Atorlip 10
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.92 | $55.00 (0%) | 🛒 Add to cart |
| 90 | $0.84 | $82.50 $76.00 (8%) | 🛒 Add to cart |
| 120 | $0.81 | $110.00 $97.00 (12%) | 🛒 Add to cart |
| 180 | $0.77 | $165.00 $139.00 (16%) | 🛒 Add to cart |
| 270 | $0.74 | $247.50 $201.00 (19%) | 🛒 Add to cart |
| 360 | $0.73
Best per pill | $330.00 $264.00 (20%) | 🛒 Add to cart |
Atorlip 10 is a prescription medication containing atorvastatin calcium, a potent lipid-lowering agent belonging to the statin class. It is specifically formulated to reduce elevated levels of low-density lipoprotein (LDL) cholesterol, triglycerides, and apolipoprotein B, while moderately increasing high-density lipoprotein (HDL) cholesterol in adult patients. Clinical evidence supports its role in primary and secondary prevention of cardiovascular events, including myocardial infarction and stroke, particularly in individuals with multiple risk factors or established coronary heart disease. Administration requires careful medical supervision, adherence to therapeutic lifestyle changes, and regular monitoring of lipid profiles and liver enzymes to ensure both efficacy and safety.
Features
- Active ingredient: Atorvastatin calcium 10 mg
- Pharmaceutical form: Film-coated tablets
- Mechanism: Selective, competitive inhibitor of HMG-CoA reductase
- Bioavailability: Approximately 14%
- Half-life: 14 hours; active metabolites contribute to prolonged effect
- Excretion: Primarily via hepatic metabolism and biliary elimination
Benefits
- Significantly reduces LDL cholesterol levels by 35–50% at the 10 mg dose
- Lowers risk of major cardiovascular events, including heart attack and ischemic stroke
- Slows progression of atherosclerosis and may promote plaque stabilization
- Improves overall lipid profile by reducing triglycerides and raising HDL cholesterol
- Offers convenient once-daily dosing, supporting long-term adherence
- Backed by extensive clinical trial data demonstrating safety and efficacy across diverse populations
Common use
Atorlip 10 is indicated as an adjunct to diet and lifestyle modifications for the treatment of hypercholesterolemia, including heterozygous familial and non-familial forms, and mixed dyslipidemia. It is prescribed for primary prevention of cardiovascular disease in patients with multiple risk factors such as hypertension, diabetes, smoking, or family history, and for secondary prevention in those with established coronary artery disease. The medication is also used in homozygous familial hypercholesterolemia when other lipid-lowering treatments are insufficient or not tolerated.
Dosage and direction
The recommended starting dose is 10 mg once daily, taken at any time of day with or without food. Dosage may be adjusted based on lipid-lowering response and therapeutic goals, with a range of 10–80 mg daily. Maximum LDL reduction typically occurs within 2–4 weeks; lipid levels should be reassessed after 2–4 weeks and dosage adjusted accordingly. For patients requiring coadministration with certain CYP3A4 inhibitors, dose limitations may apply. Tablets should be swallowed whole with water and not crushed or chewed.
Precautions
Liver function tests (ALT, AST) should be performed before initiation, at 12 weeks following start or dose increase, and periodically thereafter. Use with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Monitor for muscle pain, tenderness, or weakness; assess CPK levels if symptoms occur. Blood glucose levels should be monitored due to possible increases in HbA1c and fasting serum glucose. Not recommended during pregnancy or in women of childbearing potential not using contraception. Elderly patients may require closer monitoring due to potential for increased systemic exposure.
Contraindications
Hypersensitivity to atorvastatin or any component of the formulation; active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal; pregnancy and breastfeeding; concomitant use with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products.
Possible side effects
Common (≥1/100 to <1/10): headache, nausea, constipation, diarrhea, flatulence, dyspepsia, arthralgia, myalgia, increased blood glucose levels. Uncommon (≥1/1,000 to <1/100): insomnia, dizziness, blurred vision, tinnitus, vomiting, abdominal pain, hepatitis, alopecia, pruritus, rash, fatigue, asthenia, peripheral edema. Rare (≥1/10,000 to <1/1,000): anaphylaxis, angioedema, lupus-like syndrome, pancreatitis, gynecomastia, tendon rupture. Very rare (<1/10,000): immune-mediated necrotizing myopathy, rhabdomyolysis with renal dysfunction, hepatic failure, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, memory loss, depression.
Drug interaction
Strong CYP3A4 inhibitors significantly increase atorvastatin exposure and risk of myopathy; concomitant use is contraindicated. Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, amiodarone) may increase exposure; consider using lower doses. Gemfibrozil and other fibrates increase risk of myopathy; use only with close monitoring. Niacin (>1 g/day), colchicine, and cyclosporine increase myopathy risk. Oral contraceptives containing ethinyl estradiol and norgestrel may have increased AUC. Digoxin levels may be slightly increased; monitor appropriately. Warfarin: may potentiate anticoagulant effect; monitor INR frequently during initiation and titration.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed one. Resume the regular dosing schedule with the next dose. Consistent daily administration is important for maintaining lipid-lowering effects.
Overdose
There is no specific antidote for atorvastatin overdose. Symptomatic and supportive measures should be implemented. Gastric lavage may be considered if performed soon after ingestion. Monitor for signs and symptoms of myopathy and renal impairment. Liver function should be monitored. Hemodialysis is not expected to significantly enhance elimination due to extensive protein binding.
Storage
Store below 30°C (86°F) in the original container to protect from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging. Do not flush medications down the toilet or pour into drainage unless instructed to do so.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis, treatment decisions, and personalized medical guidance. Do not initiate, discontinue, or change dosage without medical supervision. The prescribing physician should be aware of the patient’s complete medical history, concomitant medications, and risk factors.
Reviews
“After 6 months on Atorlip 10, my LDL dropped from 190 to 98 mg/dL without significant side effects. The once-daily regimen is convenient and fits well with my other medications.” — John D., 58, with familial hypercholesterolemia.
“As a cardiologist, I find Atorlip 10 provides predictable LDL reduction with a favorable safety profile in most patients. It’s my first-line statin for moderate hypercholesterolemia.” — Dr. Elena M., Cardiologist.
“Experienced mild muscle stiffness during the first month, but it resolved with continued use. Lipid control has been excellent—my coronary risk assessment improved significantly.” — Maria S., 62, post-MI patient.